Canakinumab

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Canakinumab is a drug catalogued in DrugCentral. It was first approved by the FDA in 2009. DrugCentral lists 1 molecular target, including IL1B. Recorded indications include Articular gout, Cryopyrin associated periodic syndrome, Deficiency of mevalonate kinase and Familial Mediterranean fever.

• Molecular targets: IL1B (1 listed in DrugCentral).
• Indications: Articular gout, Cryopyrin associated periodic syndrome, Deficiency of mevalonate kinase, Familial Mediterranean fever and Systemic onset juvenile chronic arthritis and others.
• ATC code: L04AC08 (Interleukin inhibitors).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (6)

• Articular gout
• Cryopyrin associated periodic syndrome
• Deficiency of mevalonate kinase
• Familial Mediterranean fever
• Systemic onset juvenile chronic arthritis
• TNF receptor-associated periodic fever syndrome (TRAPS)

Mechanism & targets

Molecular targets (1)

Target	Gene	Action	Activity
Interleukin-1 beta	IL1B	other	—

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2011-09-26	PMDA	—	Novartis Pharma K.K.	Yes
2009-10-23	EMA	—	—
2009-06-17	FDA	—	NOVARTIS PHARMS

ATC classification

ATC code	Therapeutic hierarchy
L04AC08	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Interleukin inhibitors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Apparent death	1217.9
Inappropriate schedule of product administration	1156.5
Haemophagocytic lymphohistiocytosis	713.0
Diverticulitis	660.7
Pyrexia	429.3
Pulmonary thrombosis	409.0
Deep vein thrombosis	358.3
Terminal state	352.9
Pulmonary embolism	315.9
Renal failure	270.0
Red blood cell sedimentation rate increased	265.6
Growth retardation	259.0

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: 914613-48-2
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Canakinumab used for?

DrugCentral lists the following indications for Canakinumab: Articular gout, Cryopyrin associated periodic syndrome, Deficiency of mevalonate kinase, Familial Mediterranean fever, Systemic onset juvenile chronic arthritis and TNF receptor-associated periodic fever syndrome (TRAPS).

How does Canakinumab work?

Its molecular targets in DrugCentral include IL1B.

When was Canakinumab first approved?

Canakinumab was first approved by the FDA in 2009.

Sources

• DrugCentral drug card 4952 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201834 — compound record and bioactivity
• DrugBank DB06168 — drug record
• FDA UNII 37CQ2C7X93 — substance identity
• DailyMed: FDA labels for Canakinumab — current prescribing information (label search)
• UniProt P01584 (IL1B) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.